Hormone Health Hub: Expert Insights on Testing, Balance & Better Living — aromatase inhibitors

Single nucleotide variations (SNVs) in the enzymes that metabolise estrogen can significantly alter breast cancer risk — in some cases by as much as 12-fold when multiple variants combine. In this detailed scientific overview, Jillian Harrington PhD of ZRT Laboratory explains how variations in CYP11A1, CYP19A1 (aromatase), CYP1B1, COMT and MnSOD affect the estrogen metabolism pathway, why catechol estrogens are dangerous, and how methylation testing can reveal individual vulnerability.

Breast cancer is not one disease — it encompasses many distinct types with different attributes, degrees of invasiveness and treatment responses. Understanding the difference between invasive and non-invasive cancers, what hormone receptor status means, and which risk factors are modifiable can help women make more informed decisions about screening, lifestyle and hormone health. This article provides a clear, evidence-based overview.

The latest research confirms what Dr. John Lee and Dr. David Zava argued decades ago: maintaining healthy progesterone levels in proper balance with oestrogen is one of the most powerful tools women have for preventing and recovering from breast cancer. This article outlines seven practical steps to restore hormone balance and reduce breast cancer risk.

A landmark study published in Nature confirmed what Dr. John Lee and Dr. David Zava argued over a decade ago: natural progesterone — unlike synthetic progestins — can slow or even shrink ER+/PR+ breast cancer tumours. This article explains the receptor science behind the findings and what it means for women’s hormone health.